Becton Dickinson and Co (BDX) Hisse Fiyat
Becton Dickinson and Co Fiyat
Gelir, son 19 yılda yıllık bileşik %6,1 artarak 19,46 Md USD seviyesine ulaştı. Hisse başına kâr, son 19 yılda yıllık %0,9 büyüdü. Becton Dickinson and Co şirketinde net marj %5,9 seviyesinde bulunuyor; birkaç yıl önceki %9,4 seviyesine göre geriledi. Becton Dickinson and Co şu anda yaklaşık %1,96 temettü verimi sunuyor. Temettü dağıtım oranı, kârın yaklaşık %70 düzeyindedir. Temettü, son 19 yılda yıllık %7,7 artış gösterdi. Analistler 190,00 USD medyan fiyat hedefi belirliyor; bu, güncel fiyatın %11,4 altında bir seviyeye işaret ediyor. 21 analistten 12 tanesi hisse için alım öneriyor — genel konsensüs: Al.
Becton Dickinson and Co hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
Becton Dickinson and Co iş modeli ve hisse analizi
Becton Dickinson and Co hakkında sık sorulan sorular
Becton Dickinson and Co (BD) operates under a diversified business model. As a leading global medical technology company, BD focuses on improving healthcare delivery by developing innovative solutions. The company's business model revolves around three main segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical offers a range of medical devices, such as injection systems and infusion therapy products, to enhance patient care. BD Life Sciences focuses on research and clinical laboratories, providing products for sample management and diagnostics. BD Interventional specializes in devices for minimally invasive procedures, contributing to improved patient outcomes. Becton Dickinson and Co's business model aims to address critical healthcare challenges by delivering reliable and effective solutions.
Becton Dickinson and Co is primarily active in the healthcare industry, specifically focusing on medical technology and devices.
The main competitors of Becton Dickinson and Co in the market are Thermo Fisher Scientific Inc., Cardinal Health Inc., and Johnson & Johnson.
Becton Dickinson and Co, commonly known as BD, is a leading global medical technology company. Founded in 1897, BD has a rich history and a strong reputation in the healthcare industry. The company specializes in medical devices, instrument systems, and reagents used by healthcare professionals for diagnostic and therapeutic purposes. With over a century of experience, BD has grown to become a trusted provider of innovative solutions that improve the quality of patient care. Headquartered in Franklin Lakes, New Jersey, BD operates in more than 190 countries worldwide, serving hospitals, laboratories, healthcare professionals, and patients with its diverse portfolio of products.
Becton Dickinson and Co has achieved several significant milestones throughout its history. The company pioneered the development of the first-ever sterile disposable syringe, which revolutionized healthcare practices worldwide. They also introduced the first medical-grade plastic blood collection tube, improving patient safety and sample integrity. Becton Dickinson and Co expanded its global presence by acquiring C.R. Bard, a leading medical technology company specializing in vascular, urology, and oncology products. This strategic move enhanced their product portfolio and market reach. Furthermore, the company has consistently focused on innovation, manufacturing high-quality medical devices, laboratory equipment, and diagnostic tools. Becton Dickinson and Co continues to drive advancements in healthcare, improving patient outcomes globally.
Becton Dickinson and Co is primarily present in numerous countries and regions across the globe. The company operates in various key markets, including the United States, Europe, Asia-Pacific, Latin America, and the Middle East. With its strong global presence, Becton Dickinson and Co has established a solid market foothold, allowing it to cater to a diverse range of customers and meet their healthcare needs effectively.
Becton Dickinson and Co represents a strong commitment to quality and innovation in the healthcare industry. The company's corporate philosophy revolves around improving patient outcomes through advanced medical technologies and solutions. By prioritizing patient safety and healthcare efficiency, Becton Dickinson has established itself as a leading provider of medical devices, diagnostic systems, and pharmaceutical systems. Their values include integrity, collaboration, and customer focus, emphasizing the importance of ethical behavior, teamwork, and meeting customer needs. Becton Dickinson and Co's dedication to advancing healthcare makes it a trusted partner for healthcare professionals worldwide.
Analistler şu anda Becton Dickinson and Co hissesi için ortalama 186,88 USD hedef fiyat belirliyor (medyan: 190,00 USD); bu, son fiyata göre -12,9 % anlamına gelir. Konsensüs 21 analist notuna dayanır.
21 analist şu anda Becton Dickinson and Co hissesini değerlendiriyor: 12 al, 8 tut, 1 sat öneriyor.
Güncel döviz kuruyla Becton Dickinson and Co hissesi 193,82 EUR (214,52 USD) seviyesindedir.
Becton Dickinson and Co hissesi (BDX) 10 borsada işlem görür, bunlar arasında: NYSE (BDX), London (0R19.L), SIX (Zürich) (BDX.SW), XETRA (BOX.DE), Frankfurt (BOX.F), München (BOX.MU), Düsseldorf (BOX.DU), Wien (BDX.VI).
Becton Dickinson and Co. (BD) is a global leading medical technology company that specializes in diagnostics, instruments, and systems for medical therapy, laboratories, and life science research. The company is headquartered in New Jersey, USA, and operates in over 190 countries worldwide. The company is divided into three main business segments: BD Medical, BD Life Sciences, and BD Interventional. Each of these segments offers various products and services tailored to the needs of customers in the respective industries. BD Medical specializes in the development, manufacturing, and marketing of medical devices, insulin syringes, needles, and clinical diagnostic instruments. The goal of BD Medical is to help patients improve healthcare and reduce costs through innovative solutions. Some well-known products from BD Medical include BD Vacutainer blood collection systems, BD BACTEC systems for bacterial culture, BD Nexiva Closed I.V. catheter, and BD insulin syringes. BD Life Sciences specializes in the areas of biosciences and research. The company offers a wide range of products and services, including instruments and reagents for molecular biology, infectious diseases, and cancer research. BD Life Sciences supports scientists worldwide in the search for new diagnostic and treatment methods for diseases. Some well-known products from BD Life Sciences include BD FACSFlow Sheath Fluid, BD MAX systems for PCR amplification of DNA and RNA, and BD SurePath vials for cytological diagnosis. BD Interventional offers a variety of products and solutions for interventional medical technology. Key products from BD Interventional include catheters, stents, dilators, guide wires, and implantable devices such as pacemakers and defibrillators. The goal of BD Interventional is to provide surgeons and other medical professionals with the best possible tools and devices to safely and effectively treat patients and minimize the risk of complications. BD is also active in other business segments, such as the oil and gas industry and environmental analysis. The company also offers a wide range of professional services, training, and support to help professionals and customers effectively utilize BD's products and solutions. BD relies on continuous innovation to continuously improve its products and always provide customers with the best quality and performance. The company invests in research and development every year and collaborates closely with medical professionals and scientists to meet the demands of markets and customers. In summary, BD is a leading medical technology company focused on providing innovative products and solutions for the biosciences, clinical diagnostics, interventional medicine, and other industries. The company relies on a wide range of products and services, as well as continuous innovation and collaboration. With its global presence and commitment to quality and performance, BD positions itself as one of the key providers for the medical industry.
'nin Becton Dickinson and Co hasılatı 19,46 Md USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
'nin Becton Dickinson and Co karı 1,15 Md USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Becton Dickinson and Co'nin Fiyat/Kazanç (F/K) oranı şu anda 51,30'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Becton Dickinson and Co hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Becton Dickinson and Co'nin Fiyat/Satış (F/S) oranı şu anda 3,02'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Becton Dickinson and Co hisse senedinin değerleme metriği olarak hizmet eder.
Becton Dickinson and Co'nin Eulerpool Kalite Puanı 2/10'dur.
Becton Dickinson and Co'nin ISIN'i US0758871091'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Becton Dickinson and Co'nin WKN'i 857675'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Becton Dickinson and Co'nin ticker'ı BDX'dir. Ticker sembolü, Becton Dickinson and Co hisseleri borsada işlem görmek için kullanılır.
Becton Dickinson and Co Hissesi
Becton Dickinson and Co Emsaller Grubu
Becton Dickinson and Co Ticker
Becton Dickinson and Co FIGI
Becton Dickinson and Co'nin tüm temel göstergeleri ve derinlemesine analizi
Becton Dickinson and Co hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Becton Dickinson and Co şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: